Liver Cirrhosis Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, Japan, China - Size and Forecast 2024-2028

Published: Nov 2023 Pages: 154 SKU: IRTNTR76818

Liver Cirrhosis Therapeutics Market Forecast 2024-2028

The global liver cirrhosis therapeutics market size is estimated to grow by USD 1.94 billion at a CAGR of 5.58% between 2023 and 2028. 

The global liver cirrhosis therapeutics market is being driven primarily by the rising incidence of liver diseases, particularly hepatitis and NAFLD. According to the World Health Organization (WHO) estimates, about 325 million people worldwide suffer from viral hepatitis alone, which raises the risk of liver cirrhosis. Moreover, the spike in metabolic syndrome and obesity-related disorders, including NAFLD, is driving up the need for efficient treatments. For example, the prevalence of NAFLD is increasing, impacting about 25% of the world's population. This highlights the need for sophisticated and easily available therapies. As a result of the increasing risk of cirrhosis associated with certain liver diseases, the global is expected to expand during the forecast period.

What will be the size of the Liver Cirrhosis Therapeutics Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation by Type, End-user and Geography Analysis

Type Analysis 

Oral Segment

The market share growth by the oral segment will be significant during the forecast period. The oral type emerges as the market leader in the dynamic global market, indicating a paradigm shift in therapeutic approaches. Oral medications are becoming increasingly popular because of their patient-friendly qualities.

Get a glance at the market contribution of various segments Download PDF Sample

The oral segment was the largest and was valued at  USD 3.81 billion in 2018. One example of an innovative drug is Obet cholic acid. Oral therapies such as medicines for non-alcoholic fatty liver disease (NAFLD) and antifibrotic medications are in high demand as people prioritize convenience and ease of administration. This development is being driven by industry efforts to improve treatment adherence in addition to patient preferences. The development of novel oral formulations that target particular pathways in the evolution of liver cirrhosis highlights the effectiveness and promise of this therapeutic strategy. This market scenario highlights an optimistic tendency and positions oral treatments as a key segment in the evolving market in focus. This, in turn, will drive the growth of global liver cirrhosis therapeutics during the forecast period.

End-user Segment

The global market is expected to be dominated by hospitals as the primary distribution channel. Hospitals' pivotal role in patient care and treatment is driving this expansion. Hospitals enable easy access to liver cirrhosis therapeutics by providing a wide range of medical services under one roof. Prominent medical centres such as Cleveland Clinic and Mayo Clinic are noteworthy instances of the way they use their expertise to improve liver cirrhosis therapeutics. Hospitals remain a primary distribution channel for liver cirrhosis therapeutics, as evidenced by the faith that patients have in hospital-based healthcare. Such factors are expected to increase the adoption of hospitals as a distribution channel and hence drive the growth of the liver cirrhosis therapeutics market during the forecast period.

 

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period.  The regional market is expanding rapidly, propelled by factors such as the increased prevalence of liver disorders, growing public awareness, and sophisticated healthcare infrastructure. Over 630,000 persons were diagnosed with liver cirrhosis in the US alone in 2020, as the condition's incidence has been rising gradually. The increasing load has encouraged pharmaceutical companies to spend on R and D, which has resulted in the release of novel treatments. Drugs like Obet cholic acid, which have the approval of the FDA to treat liver fibrosis brought on by non-alcoholic steatohepatitis (NASH), are witnessing a sharp increase in use in the regional market.

In addition, the regional market's growth is further aided by the existence of major players like Gilead Sciences and Intercept Pharmaceuticals, as well as tactical alliances between drug manufacturers and healthcare providers. The region's dedication to developing medicinal solutions and meeting the growing healthcare needs related to liver cirrhosis is demonstrated by the rise of the market in focus, which in turn is expected to drive the growth of the regional liver cirrhosis therapeutics market during the forecast period.

Buy the Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 18 market companies, including:

Alnylam Pharmaceuticals Inc. - The company offers liver cirrhosis therapeutics such as siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver diseases.

  • AbbVie Inc
  • Alnylam Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • CSL Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Gwo Xi Stem Cell Applied Technology
  • Johnson and Johnson
  • Kezar Life Sciences Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc.
  • Protagonist Therapeutics Inc.
  • Tessera Therapeutics

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the trends, and challenges. 

Key Market Trends

The trend towards personalized medicine is an emerging trend shaping the market growth. Customizing treatment plans based on unique patient characteristics, such as genetic composition, liver function, and medication response, is a trend toward personalized medicine in the global market. This strategy seeks to maximize therapeutic results, reduce side effects, and improve patients' general quality of life. Genetic profiling, for example, can pinpoint precise biomarkers that impact drug metabolism, making it possible to prescribe the most effective drugs for a certain patient. With a more focused and specific approach to therapy, this trend represents a move away from a one-size-fits-all strategy and towards better patient outcomes and higher therapeutic efficacy.

Moreover, the global market is undergoing a paradigm change towards more personalized and patient-centred therapy as precision medicine continues to progress. Hence, the trend toward personalized liver cirrhosis therapeutics is expected to drive the growth of the market during the forecast period.

Key Market Challenges

The high cost of liver cirrhosis therapeutics is a significant challenge hindering market growth. A major challenge in the global market is the high cost of liver cirrhosis therapeutics, which prevents certain patient groups from accessing them. Immunosuppressants and antiviral medications for hepatitis may need extensive courses, which adds significantly to the cost of care. Furthermore, sophisticated treatments such as liver transplantation, which may be a curative measure for end-stage cirrhosis, come with extremely high expenses associated with the surgery, the recovery period following the procedure, and the lifetime immunosuppressive drugs. People who live in areas with minimal healthcare resources or who have limited healthcare coverage are disproportionately affected by this financial hardship.

For instance, the cost barrier keeps many people from getting timely and effective liver cirrhosis therapies in underdeveloped nations, where affordability is a major concern. This exacerbates health disparities globally. Hence, the high cost of liver cirrhosis therapeutics is expected to be a constraint for the wide-scale adoption of liver cirrhosis therapeutics, which, in turn, will hinder the growth of the market during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Market Analyst Overview

In the realm of hepatology, addressing liver disease treatment is paramount, particularly in combating cirrhosis medications. As fibrosis progression leads to hepatic decompensation and liver failure management, effective interventions are crucial. The market for liver health solutions, including hepatoprotective agents and antifibrotic therapies, is witnessing significant growth, driven by escalating cases of alcoholic liver disease and viral hepatitis treatment needs.

Market research and growth indicate a promising trajectory for ascites treatment and managing portal hypertension and hepatic encephalopathy. Innovative approaches to liver regeneration offer hope for patients. Market forecasting underscores the importance of strategic planning in this evolving landscape, where advancements in liver damage therapeutics continue to emerge, shaping the future of liver cirrhosis therapeutics.

Segment Overview

The market report forecasts market growth analysis by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • Type Outlook
    • Oral
    • Injection
  • End-user Outlook
    • Hospitals
    • Clinics
    • Research and academic institutes
  • Region Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest Of World 
      • Brazil
      • Argentina 
      • Australia 

 Market Scope

Report Coverage

Details

Page number

154

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 5.58%

Market Growth 2024-2028

USD 1.94 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

4.57

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 41%

Key countries

US, Germany, UK, Japan, and China

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, CSL Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Gwo Xi Stem Cell Applied Technology, Johnson and Johnson, Kezar Life Sciences Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Protagonist Therapeutics Inc., and Tessera Therapeutics

Market dynamics

Parent market analysis, market growth and forecasting inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. 

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the market between 2024 and 2028
  • Precise estimation of the liver cirrhosis therapeutics market size and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies' position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of liver cirrhosis therapeutics market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global liver cirrhosis therapeutics market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global liver cirrhosis therapeutics market 2018 - 2022 ($ billion)
    • 4.2 Type Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Type Segment 2018 - 2022 ($ billion)
    • 4.3 End-user Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – End-user Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Type

    • 6.1 Market segments
      • Exhibit 30: Chart on Type - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
    • 6.2 Comparison by Type
      • Exhibit 32: Chart on Comparison by Type
      • Exhibit 33: Data Table on Comparison by Type
    • 6.3 Oral - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
    • 6.4 Injection - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Injection - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Injection - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Injection - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Injection - Year-over-year growth 2023-2028 (%)
    • 6.5 Market opportunity by Type
      • Exhibit 42: Market opportunity by Type ($ billion)
      • Exhibit 43: Data Table on Market opportunity by Type ($ billion)

    7 Market Segmentation by End-user

    • 7.1 Market segments
      • Exhibit 44: Chart on End-user - Market share 2023-2028 (%)
      • Exhibit 45: Data Table on End-user - Market share 2023-2028 (%)
    • 7.2 Comparison by End-user
      • Exhibit 46: Chart on Comparison by End-user
      • Exhibit 47: Data Table on Comparison by End-user
    • 7.3 Hospitals - Market size and forecast 2023-2028
      • Exhibit 48: Chart on Hospitals - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 49: Data Table on Hospitals - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 50: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
      • Exhibit 51: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
    • 7.4 Clinics - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Clinics - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on Clinics - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on Clinics - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Clinics - Year-over-year growth 2023-2028 (%)
    • 7.5 Research and academic institutes - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Research and academic institutes - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on Research and academic institutes - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on Research and academic institutes - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Research and academic institutes - Year-over-year growth 2023-2028 (%)
    • 7.6 Market opportunity by End-user
      • Exhibit 60: Market opportunity by End-user ($ billion)
      • Exhibit 61: Data Table on Market opportunity by End-user ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 63: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 64: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 65: Chart on Geographic comparison
      • Exhibit 66: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 UK - Market size and forecast 2023-2028
      • Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.10 Japan - Market size and forecast 2023-2028
      • Exhibit 95: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.11 China - Market size and forecast 2023-2028
      • Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 103: Market opportunity by geography ($ billion)
      • Exhibit 104: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 105: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 107: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 108: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 109: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 110: Matrix on vendor position and classification
            • 12.3 Alnylam Pharmaceuticals Inc.
              • Exhibit 111: Alnylam Pharmaceuticals Inc. - Overview
              • Exhibit 112: Alnylam Pharmaceuticals Inc. - Product / Service
              • Exhibit 113: Alnylam Pharmaceuticals Inc. - Key news
              • Exhibit 114: Alnylam Pharmaceuticals Inc. - Key offerings
            • 12.4 Astellas Pharma Inc.
              • Exhibit 115: Astellas Pharma Inc. - Overview
              • Exhibit 116: Astellas Pharma Inc. - Product / Service
              • Exhibit 117: Astellas Pharma Inc. - Key news
              • Exhibit 118: Astellas Pharma Inc. - Key offerings
            • 12.5 AstraZeneca Plc
              • Exhibit 119: AstraZeneca Plc - Overview
              • Exhibit 120: AstraZeneca Plc - Product / Service
              • Exhibit 121: AstraZeneca Plc - Key news
              • Exhibit 122: AstraZeneca Plc - Key offerings
            • 12.6 CSL Ltd.
              • Exhibit 123: CSL Ltd. - Overview
              • Exhibit 124: CSL Ltd. - Business segments
              • Exhibit 125: CSL Ltd. - Key offerings
              • Exhibit 126: CSL Ltd. - Segment focus
            • 12.7 F. Hoffmann La Roche Ltd.
              • Exhibit 127: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 128: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 129: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 130: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 131: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.8 Gilead Sciences Inc.
              • Exhibit 132: Gilead Sciences Inc. - Overview
              • Exhibit 133: Gilead Sciences Inc. - Product / Service
              • Exhibit 134: Gilead Sciences Inc. - Key news
              • Exhibit 135: Gilead Sciences Inc. - Key offerings
            • 12.9 GlaxoSmithKline Plc
              • Exhibit 136: GlaxoSmithKline Plc - Overview
              • Exhibit 137: GlaxoSmithKline Plc - Business segments
              • Exhibit 138: GlaxoSmithKline Plc - Key news
              • Exhibit 139: GlaxoSmithKline Plc - Key offerings
              • Exhibit 140: GlaxoSmithKline Plc - Segment focus
            • 12.10 Gwo Xi Stem Cell Applied Technology
              • Exhibit 141: Gwo Xi Stem Cell Applied Technology - Overview
              • Exhibit 142: Gwo Xi Stem Cell Applied Technology - Product / Service
              • Exhibit 143: Gwo Xi Stem Cell Applied Technology - Key offerings
            • 12.11 Johnson and Johnson
              • Exhibit 144: Johnson and Johnson - Overview
              • Exhibit 145: Johnson and Johnson - Business segments
              • Exhibit 146: Johnson and Johnson - Key news
              • Exhibit 147: Johnson and Johnson - Key offerings
              • Exhibit 148: Johnson and Johnson - Segment focus
            • 12.12 Kezar Life Sciences Inc.
              • Exhibit 149: Kezar Life Sciences Inc. - Overview
              • Exhibit 150: Kezar Life Sciences Inc. - Product / Service
              • Exhibit 151: Kezar Life Sciences Inc. - Key news
              • Exhibit 152: Kezar Life Sciences Inc. - Key offerings
            • 12.13 Merck KGaA
              • Exhibit 153: Merck KGaA - Overview
              • Exhibit 154: Merck KGaA - Business segments
              • Exhibit 155: Merck KGaA - Key news
              • Exhibit 156: Merck KGaA - Key offerings
              • Exhibit 157: Merck KGaA - Segment focus
            • 12.14 Novartis AG
              • Exhibit 158: Novartis AG - Overview
              • Exhibit 159: Novartis AG - Business segments
              • Exhibit 160: Novartis AG - Key offerings
              • Exhibit 161: Novartis AG - Segment focus
            • 12.15 Novo Nordisk AS
              • Exhibit 162: Novo Nordisk AS - Overview
              • Exhibit 163: Novo Nordisk AS - Business segments
              • Exhibit 164: Novo Nordisk AS - Key offerings
              • Exhibit 165: Novo Nordisk AS - Segment focus
            • 12.16 Pfizer Inc.
              • Exhibit 166: Pfizer Inc. - Overview
              • Exhibit 167: Pfizer Inc. - Product / Service
              • Exhibit 168: Pfizer Inc. - Key news
              • Exhibit 169: Pfizer Inc. - Key offerings
            • 12.17 Protagonist Therapeutics Inc.
              • Exhibit 170: Protagonist Therapeutics Inc. - Overview
              • Exhibit 171: Protagonist Therapeutics Inc. - Product / Service
              • Exhibit 172: Protagonist Therapeutics Inc. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 173: Inclusions checklist
                • Exhibit 174: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 175: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 176: Research methodology
                • Exhibit 177: Validation techniques employed for market sizing
                • Exhibit 178: Information sources
              • 13.5 List of abbreviations
                • Exhibit 179: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              liver cirrhosis therapeutics market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis